829 related articles for article (PubMed ID: 21742772)
1. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression.
Chmielewski M; Kopecky C; Hombach AA; Abken H
Cancer Res; 2011 Sep; 71(17):5697-706. PubMed ID: 21742772
[TBL] [Abstract][Full Text] [Related]
2. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
3. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.
Hombach A; Hombach AA; Abken H
Gene Ther; 2010 Oct; 17(10):1206-13. PubMed ID: 20555360
[TBL] [Abstract][Full Text] [Related]
4. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
5. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
[TBL] [Abstract][Full Text] [Related]
6. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.
Chmielewski M; Hombach AA; Abken H
Immunol Rev; 2014 Jan; 257(1):83-90. PubMed ID: 24329791
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
[TBL] [Abstract][Full Text] [Related]
8. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents.
Sharifzadeh Z; Rahbarizadeh F; Shokrgozar MA; Ahmadvand D; Mahboudi F; Jamnani FR; Moghimi SM
Cancer Lett; 2013 Jul; 334(2):237-44. PubMed ID: 22902507
[TBL] [Abstract][Full Text] [Related]
9. Dual-specific T cells combine proliferation and antitumor activity.
Kershaw MH; Westwood JA; Hwu P
Nat Biotechnol; 2002 Dec; 20(12):1221-7. PubMed ID: 12415288
[TBL] [Abstract][Full Text] [Related]
10. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP
Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.
Henderson MA; Yong CS; Duong CP; Davenport AJ; John LB; Devaud C; Neeson P; Westwood JA; Darcy PK; Kershaw MH
Immunotherapy; 2013 Jun; 5(6):577-90. PubMed ID: 23725282
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
13. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses.
You Z; Hester J; Rollins L; Spagnoli GC; van der Bruggen P; Chen SY
Cancer Res; 2001 Jan; 61(1):197-205. PubMed ID: 11196161
[TBL] [Abstract][Full Text] [Related]
14. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
Shirasu N; Kuroki M
Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
[TBL] [Abstract][Full Text] [Related]
15. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
16. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
Zhang T; Barber A; Sentman CL
Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.
Sabel MS; Arora A; Su G; Mathiowitz E; Reineke JJ; Chang AE
Surgery; 2007 Nov; 142(5):749-60. PubMed ID: 17981196
[TBL] [Abstract][Full Text] [Related]
18. Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha.
Nishihara K; Barth RF; Wilkie N; Lang JC; Oda Y; Kikuchi H; Everson MP; Lotze MT
Cancer Gene Ther; 1995 Jun; 2(2):113-24. PubMed ID: 7621259
[TBL] [Abstract][Full Text] [Related]
19. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
20. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
